APGE

Apogee Therapeutics, Inc.

Healthcare
Biotechnology
$8.36B market cap

Forecast run · Sep 14, 2026Upside rank 2106 of 3,136

Model Signal

ForecastQ Daily Probabilities

23.5%

45.9%

32.3%

Analyst Consensus

Recommendation2.86/5 Hold

Last price$135.07

Price target$130.92

Implied move-3.1%

Analysts14

ForecastQ Portfolios

APGE is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.